Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study.
Cooperative Health Research In South Tyrol
Microbiota
NAFLD
Type 2 diabetes
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
04 12 2019
04 12 2019
Historique:
received:
26
06
2019
accepted:
07
11
2019
entrez:
6
12
2019
pubmed:
6
12
2019
medline:
10
9
2020
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is characterized by triglyceride accumulation in the hepatocytes in the absence of alcohol overconsumption, commonly associated with insulin resistance and obesity. Both NAFLD and type 2 diabetes (T2D) are characterized by an altered microbiota composition, however the role of the microbiota in NAFLD and T2D is not well understood. To assess the relationship between alteration in the microbiota and NAFLD while dissecting the role of T2D, we established a nested study on T2D and non-T2D individuals within the Cooperative Health Research In South Tyrol (CHRIS) study, called the CHRIS-NAFLD study. Here, we present the study protocol along with baseline and follow-up characteristics of study participants. Among the first 4979 CHRIS study participants, 227 individuals with T2D were identified and recalled, along with 227 age- and sex-matched non-T2D individuals. Participants underwent ultrasound and transient elastography examination to evaluate the presence of hepatic steatosis and liver stiffness. Additionally, sampling of saliva and faeces, biochemical measurements and clinical interviews were carried out. We recruited 173 T2D and 183 non-T2D participants (78% overall response rate). Hepatic steatosis was more common in T2D (63.7%) than non-T2D (36.3%) participants. T2D participants also had higher levels of liver stiffness (median 4.8 kPa, interquartile range (IQR) 3.7, 5.9) than non-T2D participants (median 3.9 kPa, IQR 3.3, 5.1). The non-invasive scoring systems like the NAFLD fibrosis score (NFS) suggests an increased liver fibrosis in T2D (mean - 0.55, standard deviation, SD, 1.30) than non-T2D participants (mean - 1.30, SD, 1.17). Given the comprehensive biochemical and clinical characterization of study participants, once the bioinformatics classification of the microbiota will be completed, the CHRIS-NAFLD study will become a useful resource to further our understanding of the relationship between microbiota, T2D and NAFLD.
Sections du résumé
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) is characterized by triglyceride accumulation in the hepatocytes in the absence of alcohol overconsumption, commonly associated with insulin resistance and obesity. Both NAFLD and type 2 diabetes (T2D) are characterized by an altered microbiota composition, however the role of the microbiota in NAFLD and T2D is not well understood. To assess the relationship between alteration in the microbiota and NAFLD while dissecting the role of T2D, we established a nested study on T2D and non-T2D individuals within the Cooperative Health Research In South Tyrol (CHRIS) study, called the CHRIS-NAFLD study. Here, we present the study protocol along with baseline and follow-up characteristics of study participants.
METHODS
Among the first 4979 CHRIS study participants, 227 individuals with T2D were identified and recalled, along with 227 age- and sex-matched non-T2D individuals. Participants underwent ultrasound and transient elastography examination to evaluate the presence of hepatic steatosis and liver stiffness. Additionally, sampling of saliva and faeces, biochemical measurements and clinical interviews were carried out.
RESULTS
We recruited 173 T2D and 183 non-T2D participants (78% overall response rate). Hepatic steatosis was more common in T2D (63.7%) than non-T2D (36.3%) participants. T2D participants also had higher levels of liver stiffness (median 4.8 kPa, interquartile range (IQR) 3.7, 5.9) than non-T2D participants (median 3.9 kPa, IQR 3.3, 5.1). The non-invasive scoring systems like the NAFLD fibrosis score (NFS) suggests an increased liver fibrosis in T2D (mean - 0.55, standard deviation, SD, 1.30) than non-T2D participants (mean - 1.30, SD, 1.17).
DISCUSSION
Given the comprehensive biochemical and clinical characterization of study participants, once the bioinformatics classification of the microbiota will be completed, the CHRIS-NAFLD study will become a useful resource to further our understanding of the relationship between microbiota, T2D and NAFLD.
Identifiants
pubmed: 31801616
doi: 10.1186/s12967-019-02130-z
pii: 10.1186/s12967-019-02130-z
pmc: PMC6891972
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
408Références
Cell Metab. 2017 May 2;25(5):1054-1062.e5
pubmed: 28467925
Expert Rev Gastroenterol Hepatol. 2008 Aug;2(4):541-52
pubmed: 19072402
Clin Gastroenterol Hepatol. 2015 Apr;13(4):643-54.e1-9; quiz e39-40
pubmed: 24768810
Gastroenterology. 2011 Oct;141(4):1249-53
pubmed: 21726509
J Transl Med. 2015 Nov 05;13:348
pubmed: 26541195
Medicine (Baltimore). 2017 Apr;96(17):e6723
pubmed: 28445288
Diabetes Care. 2011 May;34(5):1139-44
pubmed: 21478462
Obesity (Silver Spring). 2009 Sep;17(9):1783-8
pubmed: 19325543
Nature. 2006 Dec 21;444(7122):1027-31
pubmed: 17183312
Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):10011-6
pubmed: 16782812
Diabetes Care. 2010 Apr;33(4):920-2
pubmed: 20067971
Nature. 2014 Sep 4;513(7516):59-64
pubmed: 25079328
Am J Physiol Gastrointest Liver Physiol. 2011 Mar;300(3):G433-41
pubmed: 21233280
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
PLoS One. 2013 Apr 25;8(4):e62885
pubmed: 23638162
Lancet. 2005 May 7-13;365(9471):1629-35; discussion 1600-1
pubmed: 15885295
J Pain. 2018 Dec;19(12):1424-1434
pubmed: 30017960
Gastroenterology. 2009 Sep;137(3):865-72
pubmed: 19524579
J Periodontal Res. 2013 Feb;48(1):30-6
pubmed: 22762355
Gut. 2016 May;65(5):749-56
pubmed: 26719299
PLoS One. 2013 Aug 27;8(8):e71108
pubmed: 24013136
PLoS One. 2019 Mar 14;14(3):e0213692
pubmed: 30870486
Am J Gastroenterol. 2009 Apr;104(4):861-7
pubmed: 19293782
Nature. 2006 Dec 21;444(7122):1022-3
pubmed: 17183309
Microbiome. 2017 Aug 9;5(1):95
pubmed: 28793934
Obesity (Silver Spring). 2010 Jan;18(1):190-5
pubmed: 19498350
J Hepatol. 2011 Dec;55(6):1181-3
pubmed: 21703167
Liver Int. 2012 Sep;32(8):1242-52
pubmed: 22520641
Hepatology. 2016 Dec;64(6):2015-2027
pubmed: 27639192
Microbiome. 2018 Jun 8;6(1):101
pubmed: 29880062
World J Hepatol. 2015 Jun 28;7(12):1679-84
pubmed: 26140087
Hormones (Athens). 2019 Sep;18(3):245-250
pubmed: 30840230
Clin Gastroenterol Hepatol. 2013 Jul;11(7):868-75.e1-3
pubmed: 23454028
Eur J Clin Nutr. 2011 Jun;65(6):750-6
pubmed: 21427744
Diabetes. 2013 Oct;62(10):3341-9
pubmed: 24065795
Hepatology. 2013 Jul;58(1):120-7
pubmed: 23401313
Oral Microbiol Immunol. 2007 Jun;22(3):175-81
pubmed: 17488443
Gut. 2016 May;65(5):740-8
pubmed: 26657899
BMJ. 1990 Feb 17;300(6722):439-40
pubmed: 2107897
Crit Rev Food Sci Nutr. 2018 May 24;58(8):1294-1309
pubmed: 27892685
Nature. 2012 Oct 4;490(7418):55-60
pubmed: 23023125
World J Gastroenterol. 2014 Jul 14;20(26):8377-92
pubmed: 25024596
PLoS One. 2017 Dec 8;12(12):e0185902
pubmed: 29220367
Hum Genet. 2017 Jun;136(6):743-757
pubmed: 28374192
Sci Rep. 2018 Jan 12;8(1):662
pubmed: 29330433
BMC Gastroenterol. 2012 Feb 16;12:16
pubmed: 22340817
ISME J. 2012 Jan;6(1):46-56
pubmed: 21716308
Diabetes Care. 2007 May;30(5):1212-8
pubmed: 17277038
Abdom Imaging. 2015 Apr;40(4):698-708
pubmed: 25690689
Gastroenterology. 2011 Mar;140(3):976-86
pubmed: 21129376
Nat Commun. 2017 Oct 16;8(1):837
pubmed: 29038503
Genome Med. 2016 Apr 13;8(1):39
pubmed: 27074706
Hepatology. 2003 May;37(5):1202-19
pubmed: 12717402
Int J Obes (Lond). 2012 Jun;36(6):817-25
pubmed: 21829158
Neurogastroenterol Motil. 2016 Mar;28(3):443-8
pubmed: 26690980
Liver Int. 2013 Oct;33(9):1406-12
pubmed: 23656177
Am J Gastroenterol. 2012 Jul;107(7):1001-10
pubmed: 22710578
J Appl Microbiol. 2007 May;102(5):1197-208
pubmed: 17448155
Clin Gastroenterol Hepatol. 2019 Jan;17(1):156-163.e2
pubmed: 29705261
Cell Metab. 2014 Nov 4;20(5):753-760
pubmed: 25176147
J Bacteriol. 2010 Oct;192(19):5002-17
pubmed: 20656903
Hepatology. 2017 Feb;65(2):451-464
pubmed: 27028797
Front Cell Infect Microbiol. 2012 Oct 26;2:132
pubmed: 23112961
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
J Atheroscler Thromb. 2005;12(6):295-300
pubmed: 16394610
Tech Coloproctol. 2001 Dec;5(3):163-4
pubmed: 11875684
Gigascience. 2013 May 01;2(1):7
pubmed: 23634721
Dig Liver Dis. 2010 Jul;42(7):503-8
pubmed: 19766548
Diabetes Care. 2014 Jan;37 Suppl 1:S14-80
pubmed: 24357209
Hepatology. 2018 Jan;67(1):134-144
pubmed: 28859228
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85
pubmed: 21623852
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Liver Int. 2009 Jan;29(1):113-9
pubmed: 18384521
Hepatology. 2007 Apr;45(4):846-54
pubmed: 17393509
J Gen Intern Med. 2014 Feb;29(2):388-94
pubmed: 24002631
Ann Intern Med. 2000 Jan 18;132(2):112-7
pubmed: 10644271
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
BMC Oral Health. 2011 Dec 12;11:33
pubmed: 22152152
Hepatology. 2016 Jan;63(1):138-47
pubmed: 26171685
JCI Insight. 2017 Oct 5;2(19):
pubmed: 28978799
Nat Genet. 2019 Apr;51(4):600-605
pubmed: 30778224
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309
Hepatology. 2010 Feb;51(2):454-62
pubmed: 20101745
Hepatology. 2011 Sep 2;54(3):1082-1090
pubmed: 21618575
Hepatology. 2016 Mar;63(3):764-75
pubmed: 26600078
World J Hepatol. 2015 Apr 28;7(6):846-58
pubmed: 25937862